E-LIB Suche - Ergebnisse für: Tummala, Raj

1

Type I interferon blockade with anifrolumab in patients wit..:

Baker, Tina ; Sharifian, Hoda ; Newcombe, Paul J...
Annals of the Rheumatic Diseases. 83 (2024) 8 - p. 1018-1027 , 2024

2

Correction: Targeting DORIS Remission and LLDAS in SLE: A R..:

Parra Sánchez, Agner R. ; van Vollenhoven, Ronald F. ; Morand, Eric F....
Rheumatology and Therapy. 11 (2024) 4 - p. 1059-1061 , 2024

Link: https://doi.org/10.1007/..

3

Time to onset of clinical response to anifrolumab in patien..:

Bruce, Ian N ; van Vollenhoven, Ronald F ; Psachoulia, Konstantina...
Lupus Science & Medicine. 10 (2023) 1 - p. e000761 , 2023

Link: https://doi.org/10.1136/..

4

Targeting DORIS Remission and LLDAS in SLE: A Review:

Parra Sánchez, Agner R. ; van Vollenhoven, Ronald F. ; Morand, Eric F....
Rheumatology and Therapy. 10 (2023) 6 - p. 1459-1477 , 2023

Link: https://doi.org/10.1007/..

5

Anifrolumab in lupus nephritis: results from second-year ex..:

Jayne, David ; Rovin, Brad ; Mysler, Eduardo...
Lupus Science & Medicine. 10 (2023) 2 - p. e000910 , 2023

Link: https://doi.org/10.1136/..

6

Lupus low disease activity state attainment in the phase 3 ..:

Morand, Eric F ; Abreu, Gabriel ; Furie, Richard A..
Annals of the Rheumatic Diseases. 82 (2023) 5 - p. 639-645 , 2023

Link: https://doi.org/10.1136/..

7

Impact of SARS-CoV-2 infection on patients with systemic lu..:

Rabe, Adrian Paul J ; Loke, Wei Jie ; Kalyani, Rubana N...
BMJ Open. 13 (2023) 11 - p. e071072 , 2023

Link: https://doi.org/10.1136/..

8

Burden of systemic lupus erythematosus in clinical practice..:

Arnaud, Laurent ; Furie, Richard ; Morand, Eric F...
Lupus Science & Medicine. 10 (2023) 2 - p. e001032 , 2023

Link: https://doi.org/10.1136/..

9

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogeni..:

Tang, Weifeng ; Tummala, Raj ; Almquist, Joachim...
Clinical Pharmacokinetics. 62 (2023) 5 - p. 655-671 , 2023

Link: https://doi.org/10.1007/..

10

A Randomized, Placebo‐Controlled Phase III Extension Trial ..:

Kalunian, Kenneth C. ; Furie, Richard ; Morand, Eric F....
Arthritis & Rheumatology. 75 (2022) 2 - p. 253-265 , 2022

Link: https://doi.org/10.1002/..

11

Relationship Between Anifrolumab Pharmacokinetics, Pharmaco..:

Chia, Yen Lin ; Tummala, Raj ; Mai, Tu H....
The Journal of Clinical Pharmacology. 62 (2022) 9 - p. 1094-1105 , 2022

Link: https://doi.org/10.1002/..

12

Nonlinear Population Pharmacokinetics of Anifrolumab in Hea..:

Almquist, Joachim ; Kuruvilla, Denison ; Mai, Tu...
The Journal of Clinical Pharmacology. 62 (2022) 9 - p. 1106-1120 , 2022

Link: https://doi.org/10.1002/..

13

Concordance and discordance in SLE clinical trial outcome m..:

Bruce, Ian N ; Furie, Richard A ; Morand, Eric F...
Annals of the Rheumatic Diseases. 81 (2022) 7 - p. 962-969 , 2022

Link: https://doi.org/10.1136/..

14

Sustained glucocorticoid tapering in the phase 3 trials of ..:

Bruce, Ian N ; van Vollenhoven, Ronald F ; Morand, Eric F...
Rheumatology. 62 (2022) 4 - p. 1526-1534 , 2022

Link: https://doi.org/10.1093/..

15

Clinical meaningfulness of a British Isles Lupus Assessment..:

Strand, Vibeke ; O'Quinn, Sean ; Furie, Richard A...
The Lancet Rheumatology. 4 (2022) 3 - p. e198-e207 , 2022

Link: https://doi.org/10.1016/..